

18334 U.S. PTO  
031904

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	RLC-88
First Inventor	Donald Gibbons et al.
Title	Linear Motion Compensator
Express Mail Label No.	ET876497162US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

## ADDRESS TO:

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.
3. ☒ Specification [Total Pages \_\_\_\_\_]  
(preferred arrangement set forth below)
  - Descriptive title of the invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets \_\_\_\_\_ 9 \_\_\_\_\_]
5. Oath or Declaration [Total Sheets \_\_\_\_\_]
  - a. ☐ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 18 completed)
  - i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☐ Computer Readable Form (CRF)
  - b. Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☐ Paper
  - c. ☐ Statements verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other: \_\_\_\_\_

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application

Prior application information: Examiner \_\_\_\_\_ Art Unit: \_\_\_\_\_  
For CONTINUATION OF DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

☒ Customer Number: 23569 OR ☐ Correspondence address below

Name			
Address			
City	State	Zip Code	
Country	Telephone	Fax	

Name (Print/Type)	David R. Stacey	Registration No. (Attorney/Agent)	33,794
Signature	<i>David R. Stacey</i>	Date	3/19/04

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

17510 U.S. PTO  
10/804509  
031904

031904

1834 U.S. PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL

## for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 770.00

### Complete if Known

Application Number	
Filing Date	
First Named Inventor	Donald Gibbons et al.
Examiner Name	
Art Unit	
Attorney Docket No.	RLC-88

### METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number: 19-3875 (RLC-88)

Deposit Account Name: Square D Compay

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☐ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

### FEE CALCULATION

1. BASIC FILING FEE			
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	770.00
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1) (\$)			770.00

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims: 20 -20\*\* =  X  = 0.00

Independent Claims: 2 -3\*\* =  X  = 0.00

Multiple Dependent:  X  =

Large Entity Fee Code (\$)		Small Entity Fee Code (\$)		Fee Description	
1202 18	2202 9	1201 84	2201 42	Claims in excess of 20	
1203 280	2203 140	1204 84	2204 42	Independent claims in excess of 3	
1204 84	2204 42	1205 18	2205 9	Multiple dependent claim, if not paid	
				** Reissue independent claims over original patent	
				** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2) (\$)					0.00

\*\*or number previously paid, if greater; For Reissues, see above

### FEE CALCULATION (continued)

3. ADDITIONAL FEES						
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid			
1051 130	2051 65	Surcharge - late filing fee or oath				
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet				
1053 130	2053 130	Non-English specification				
1812 2,520	1812 2,520	For filing a request for ex parte reexamination				
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action				
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action				
1251 110	2251 55	Extension for reply within first month				
1252 410	2252 205	Extension for reply within second month				
1253 930	2253 465	Extension for reply within third month				
1254 1,450	2254 725	Extension for reply within fourth month				
1255 1,970	2255 985	Extension for reply within fifth month				
1401 320	2401 160	Notice of Appeal				
1402 320	2402 160	Filing a brief in support of an appeal				
1403 280	2403 140	Request for oral hearing				
1451 1,510	1451 1,510	Petition to institute a public use proceeding				
1452 110	2452 55	Petition to revive - unavoidable				
1453 1,300	2453 650	Petition to revive - unintentional				
1501 1,300	2501 650	Utility issue fee (or reissue)				
1502 470	2502 235	Design issue fee				
1503 630	2503 315	Plant issue fee				
1460 130	1460 130	Petitions to the Commissioner				
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)				
1806 180	1806 180	Submission of Information Disclosure Stmt				
8021 40	8021 40	Recording each patent assignment per property (times number of properties)				
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))				
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))				
1801 750	2801 375	Request for Continued Examination (RCE)				
1802 900	1802 900	Request for expedited examination of a design application				
Other fee (specify)						
*Reduced by Basic Filing Fee Paid						
SUBTOTAL (3) (\$)						0.00

SUBMITTED BY		(Complete if applicable)	
Name (Print/Type)	David R. Stacey	Registration No. (Attorney/Agent)	33,794
Signature	<i>David R. Stacey</i>	Telephone	847/925-3458
		Date	3/19/04

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

*(continued)*

Att

Att

the 1990s, the number of people in the world who are undernourished has declined from 1.1 billion to 800 million. The number of people who are malnourished has declined from 1.5 billion to 1 billion. The number of people who are obese has increased from 100 million to 300 million. The number of people who are overweight has increased from 100 million to 300 million. The number of people who are obese and overweight has increased from 100 million to 300 million. The number of people who are obese and overweight has increased from 100 million to 300 million.

## Certificate of Express

1. *Journal of the American Medical Association*, 1997; 277: 1025-1030.

Mail Stop 1  
Commissioner

Commission  
PO Box 14  
Alexandria

1. *Pharmaceuticals* (1998) 10: 101-110.  
 2. *Pharmaceuticals* (1999) 11: 101-110.  
 3. *Pharmaceuticals* (2000) 12: 101-110.  
 4. *Pharmaceuticals* (2001) 13: 101-110.  
 5. *Pharmaceuticals* (2002) 14: 101-110.  
 6. *Pharmaceuticals* (2003) 15: 101-110.  
 7. *Pharmaceuticals* (2004) 16: 101-110.  
 8. *Pharmaceuticals* (2005) 17: 101-110.  
 9. *Pharmaceuticals* (2006) 18: 101-110.  
 10. *Pharmaceuticals* (2007) 19: 101-110.  
 11. *Pharmaceuticals* (2008) 20: 101-110.  
 12. *Pharmaceuticals* (2009) 21: 101-110.  
 13. *Pharmaceuticals* (2010) 22: 101-110.  
 14. *Pharmaceuticals* (2011) 23: 101-110.  
 15. *Pharmaceuticals* (2012) 24: 101-110.  
 16. *Pharmaceuticals* (2013) 25: 101-110.  
 17. *Pharmaceuticals* (2014) 26: 101-110.  
 18. *Pharmaceuticals* (2015) 27: 101-110.  
 19. *Pharmaceuticals* (2016) 28: 101-110.  
 20. *Pharmaceuticals* (2017) 29: 101-110.  
 21. *Pharmaceuticals* (2018) 30: 101-110.  
 22. *Pharmaceuticals* (2019) 31: 101-110.  
 23. *Pharmaceuticals* (2020) 32: 101-110.  
 24. *Pharmaceuticals* (2021) 33: 101-110.  
 25. *Pharmaceuticals* (2022) 34: 101-110.  
 26. *Pharmaceuticals* (2023) 35: 101-110.  
 27. *Pharmaceuticals* (2024) 36: 101-110.  
 28. *Pharmaceuticals* (2025) 37: 101-110.  
 29. *Pharmaceuticals* (2026) 38: 101-110.  
 30. *Pharmaceuticals* (2027) 39: 101-110.  
 31. *Pharmaceuticals* (2028) 40: 101-110.  
 32. *Pharmaceuticals* (2029) 41: 101-110.  
 33. *Pharmaceuticals* (2030) 42: 101-110.  
 34. *Pharmaceuticals* (2031) 43: 101-110.  
 35. *Pharmaceuticals* (2032) 44: 101-110.  
 36. *Pharmaceuticals* (2033) 45: 101-110.  
 37. *Pharmaceuticals* (2034) 46: 101-110.  
 38. *Pharmaceuticals* (2035) 47: 101-110.  
 39. *Pharmaceuticals* (2036) 48: 101-110.  
 40. *Pharmaceuticals* (2037) 49: 101-110.  
 41. *Pharmaceuticals* (2038) 50: 101-110.  
 42. *Pharmaceuticals* (2039) 51: 101-110.  
 43. *Pharmaceuticals* (2040) 52: 101-110.  
 44. *Pharmaceuticals* (2041) 53: 101-110.  
 45. *Pharmaceuticals* (2042) 54: 101-110.  
 46. *Pharmaceuticals* (2043) 55: 101-110.  
 47. *Pharmaceuticals* (2044) 56: 101-110.  
 48. *Pharmaceuticals* (2045) 57: 101-110.  
 49. *Pharmaceuticals* (2046) 58: 101-110.  
 50. *Pharmaceuticals* (2047) 59: 101-110.  
 51. *Pharmaceuticals* (2048) 60: 101-110.  
 52. *Pharmaceuticals* (2049) 61: 101-110.  
 53. *Pharmaceuticals* (2050) 62: 101-110.  
 54. *Pharmaceuticals* (2051) 63: 101-110.  
 55. *Pharmaceuticals* (2052) 64: 101-110.  
 56. *Pharmaceuticals* (2053) 65: 101-110.  
 57. *Pharmaceuticals* (2054) 66: 101-110.  
 58. *Pharmaceuticals* (2055) 67: 101-110.  
 59. *Pharmaceuticals* (2056) 68: 101-110.  
 60. *Pharmaceuticals* (2057) 69: 101-110.  
 61. *Pharmaceuticals* (2058) 70: 101-110.  
 62. *Pharmaceuticals* (2059) 71: 101-110.  
 63. *Pharmaceuticals* (2060) 72: 101-110.  
 64. *Pharmaceuticals* (2061) 73: 101-110.  
 65. *Pharmaceuticals* (2062) 74: 101-110.  
 66. *Pharmaceuticals* (2063) 75: 101-110.  
 67. *Pharmaceuticals* (2064) 76: 101-110.  
 68. *Pharmaceuticals* (2065) 77: 101-110.  
 69. *Pharmaceuticals* (2066) 78: 101-110.  
 70. *Pharmaceuticals* (2067) 79: 101-110.  
 71. *Pharmaceuticals* (2068) 80: 101-110.  
 72. *Pharmaceuticals* (2069) 81: 101-110.  
 73. *Pharmaceuticals* (2070) 82: 101-110.  
 74. *Pharmaceuticals* (2071) 83: 101-110.  
 75. *Pharmaceuticals* (2072) 84: 101-110.  
 76. *Pharmaceuticals* (2073) 85: 101-110.  
 77. *Pharmaceuticals* (2074) 86: 101-110.  
 78. *Pharmaceuticals* (2075) 87: 101-110.  
 79. *Pharmaceuticals* (2076) 88: 101-110.  
 80. *Pharmaceuticals* (2077) 89: 101-110.  
 81. *Pharmaceuticals* (2078) 90: 101-110.  
 82. *Pharmaceuticals* (2079) 91: 101-110.  
 83. *Pharmaceuticals* (2080) 92: 101-110.  
 84. *Pharmaceuticals* (2081) 93: 101-110.  
 85. *Pharmaceuticals* (2082) 94: 101-110.  
 86. *Pharmaceuticals* (2083) 95: 101-110.  
 87. *Pharmaceuticals* (2084) 96: 101-110.  
 88. *Pharmaceuticals* (2085) 97: 101-110.  
 89. *Pharmaceuticals* (2086) 98: 101-110.  
 90. *Pharmaceuticals* (2087) 99: 101-110.  
 91. *Pharmaceuticals* (2088) 100: 101-110.  
 92. *Pharmaceuticals* (2089) 101: 101-110.  
 93. *Pharmaceuticals* (2090) 102: 101-110.  
 94. *Pharmaceuticals* (2091) 103: 101-110.  
 95. *Pharmaceuticals* (2092) 104: 101-110.  
 96. *Pharmaceuticals* (2093) 105: 101-110.  
 97. *Pharmaceuticals* (2094) 106: 101-110.  
 98. *Pharmaceuticals* (2095) 107: 101-110.  
 99. *Pharmaceuticals* (2096) 108: 101-110.  
 100. *Pharmaceuticals* (2097) 109: 101-110.  
 101. *Pharmaceuticals* (2098) 110: 101-110.  
 102. *Pharmaceuticals* (2099) 111: 101-110.  
 103. *Pharmaceuticals* (2100) 112: 101-110.  
 104. *Pharmaceuticals* (2101) 113: 101-110.  
 105. *Pharmaceuticals* (2102) 114: 101-110.  
 106. *Pharmaceuticals* (2103) 115: 101-110.  
 107. *Pharmaceuticals* (2104) 116: 101-110.  
 108. *Pharmaceuticals* (2105) 117: 101-110.  
 109. *Pharmaceuticals* (2106) 118: 101-110.  
 110. *Pharmaceuticals* (2107) 119: 101-110.